Albert Faro, MD. Credit: Larry Luxner

Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Albert Faro, MD, vice president for clinical affairs at the Cystic Fibrosis Foundation (CFF). Dr. Faro speaks about COVID-19’s impact on the cystic fibrosis (CF) community and how cystic fibrosis transmembrane conductance regulator (CFTR) modulators and better care have dramatically extended the life of patients with cystic fibrosis.

Read the full story here: COVID-19 Presents a Low Risk for Most Children With Cystic Fibrosis